Could a simple amino acid ease rare brain disorders?

NCT ID NCT07221292

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests an experimental drug, N-acetyl-L-leucine, for people with rare genetic conditions caused by changes in the CACNA1A gene. These conditions can cause problems with movement, balance, and severe migraines. The study will include 60 people aged 4 and older, and will compare the drug to a placebo to see if it improves symptoms like walking and coordination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACNA1A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • The University of Texas Health (UT Health)

    Houston, Texas, 77030, United States

  • University Hospital Bern Inselspital

    Bern, 3010, Switzerland

  • University of Cologne

    Cologne, 50937, Germany

  • University of Giessen

    Giessen, 35389, Germany

Conditions

Explore the condition pages connected to this study.